WO2000047198A3 - Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections - Google Patents

Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections Download PDF

Info

Publication number
WO2000047198A3
WO2000047198A3 PCT/US2000/003768 US0003768W WO0047198A3 WO 2000047198 A3 WO2000047198 A3 WO 2000047198A3 US 0003768 W US0003768 W US 0003768W WO 0047198 A3 WO0047198 A3 WO 0047198A3
Authority
WO
WIPO (PCT)
Prior art keywords
dideoxy
imino
substituted
hepatitis virus
treating hepatitis
Prior art date
Application number
PCT/US2000/003768
Other languages
French (fr)
Other versions
WO2000047198A2 (en
Inventor
Richard A Mueller
Martin L Bryant
Richard A Partis
Original Assignee
Searle & Co
Richard A Mueller
Martin L Bryant
Richard A Partis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co, Richard A Mueller, Martin L Bryant, Richard A Partis filed Critical Searle & Co
Priority to CA002362914A priority Critical patent/CA2362914C/en
Priority to EP00914585A priority patent/EP1165080A2/en
Priority to AU35955/00A priority patent/AU3595500A/en
Priority to JP2000598151A priority patent/JP2002536407A/en
Publication of WO2000047198A2 publication Critical patent/WO2000047198A2/en
Publication of WO2000047198A3 publication Critical patent/WO2000047198A3/en
Priority to HK02104874.1A priority patent/HK1043311A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

N-Substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds of Formula (I) are effective in treatment of hepatitis infections, including hepatitis B and hepatitis C. In treating hepatitis infections, the compounds of Formula (I) may be used alone, or in combination with another antiviral agent selected from among nucleosides, nucleotides, immunomodulators, immunostimulants or various combinations of such other agents.
PCT/US2000/003768 1999-02-12 2000-02-14 Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections WO2000047198A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002362914A CA2362914C (en) 1999-02-12 2000-02-14 Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
EP00914585A EP1165080A2 (en) 1999-02-12 2000-02-14 Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
AU35955/00A AU3595500A (en) 1999-02-12 2000-02-14 Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
JP2000598151A JP2002536407A (en) 1999-02-12 2000-02-14 Use of substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for the treatment of hepatitis virus infection
HK02104874.1A HK1043311A1 (en) 1999-02-12 2002-06-28 Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11972299P 1999-02-12 1999-02-12
US11985699P 1999-02-12 1999-02-12
US60/119,856 1999-02-12
US60/119,722 1999-02-12

Publications (2)

Publication Number Publication Date
WO2000047198A2 WO2000047198A2 (en) 2000-08-17
WO2000047198A3 true WO2000047198A3 (en) 2001-02-15

Family

ID=26817632

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/003768 WO2000047198A2 (en) 1999-02-12 2000-02-14 Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections

Country Status (10)

Country Link
US (3) US6545021B1 (en)
EP (1) EP1165080A2 (en)
JP (1) JP2002536407A (en)
AT (1) ATE402701T1 (en)
AU (1) AU3595500A (en)
CA (1) CA2362914C (en)
DE (1) DE60039729D1 (en)
ES (1) ES2311921T3 (en)
HK (1) HK1043311A1 (en)
WO (1) WO2000047198A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689759B1 (en) 1998-02-12 2004-02-10 G. D. Searle & Co. Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy
CA2362785A1 (en) 1999-02-12 2001-02-08 G.D. Searle & Co. Glucamine compounds for treating hepatitis virus infections
JP2003506406A (en) 1999-08-10 2003-02-18 ザ・チャンセラー・マスターズ・アンド・スカラーズ・オブ・ザ・ユニバーシティ・オブ・オックスフォード Long-chain N-alkyl compounds and oxa derivatives thereof
US7256005B2 (en) 1999-08-10 2007-08-14 The Chancellor, Masters And Scholars Of The University Of Oxford Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity
WO2001060366A1 (en) * 2000-02-14 2001-08-23 Pharmacia Corporation Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
KR101201552B1 (en) 2000-10-18 2012-11-15 파마셋 인코포레이티드 Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
US20040067877A1 (en) * 2002-08-01 2004-04-08 Schinazi Raymond F. 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections
AU2003302370A1 (en) * 2002-09-23 2004-06-18 The Chancellor, Masters And Scholars Of The University Of Oxford Use of iminosugar derivatives to inhibit ion channel activity
US20090111812A1 (en) * 2004-06-14 2009-04-30 Musc Foundation For Research Development Methods for treating inflammatory disorders
KR20080025373A (en) * 2005-05-17 2008-03-20 아미쿠스 세라퓨틱스, 인코포레이티드 A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
EP2399587A1 (en) 2006-08-02 2011-12-28 The University of Oxford Liposome treatment of viral infections
CA2666814A1 (en) * 2006-08-21 2008-05-29 United Therapeutics Corporation Combination therapy for treatment of viral infections
US8097728B2 (en) * 2007-04-30 2012-01-17 Philadelphia Health & Education Corporation Iminosugar compounds with antiflavirus activity
EP2282723A2 (en) * 2008-03-26 2011-02-16 University of Oxford Endoplasmic reticulum targeting liposomes
US9040488B2 (en) * 2008-09-02 2015-05-26 Baruch S. Blumberg Institute Imino sugar derivatives demonstrate potent antiviral activity and reduced toxicity
AT507745B1 (en) * 2008-12-16 2012-01-15 Forschungsholding Tu Graz Gmbh FLUOROPHILE GLYCOSIDASE INHIBITOR
KR20120042716A (en) 2009-02-23 2012-05-03 유나이티드 세러퓨틱스 코오포레이션 Iminosugars and methods of treating viral diseases
JP5951996B2 (en) * 2009-02-24 2016-07-13 ユナイテッド セラピューティクス コーポレーション Methods for treating iminosugars and arenavirus infections
CN102427804A (en) * 2009-03-27 2012-04-25 牛津大学之校长及学者 Cholesterol level lowering liposomes
EP2440205B1 (en) 2009-06-12 2014-08-27 United Therapeutics Corporation Iminosugars for use in the treatment of bunyaviral and togaviral diseases
EP2473046B1 (en) 2009-09-04 2014-10-22 United Therapeutics Corporation Iminosugars for their use in the treatment of filoviral diseases
BR112012004676A2 (en) * 2009-09-04 2019-09-24 United Therapeutics Corp method of treating orotomixoviral infections.
CA2772807A1 (en) * 2009-09-04 2011-03-10 The Chancellor, Masters And Scholars Of The University Of Oxford Methods of treating poxviral infections
JP6236406B2 (en) 2012-03-07 2017-11-22 アミカス セラピューティックス インコーポレイテッド High concentration α-glucosidase composition for the treatment of Pompe disease
CN104703597A (en) 2012-06-06 2015-06-10 尤尼特尔滤过性微生物学有限责任公司 Novel iminosugars and their applications
RU2702133C2 (en) 2013-09-16 2019-10-04 ЭМЕРГЕНТ ВИРОЛОДЖИ ЭлЭлСи Deoxynoyirimicin derivatives and methods for use thereof
WO2015123385A1 (en) * 2014-02-12 2015-08-20 Amicus Therapeutics, Inc. Sugar derivatives comprising sulfur-containing moieties and methods of making same and methods of using the same for the treatment of mps iiic
PT3201320T (en) 2014-09-30 2024-01-12 Amicus Therapeutics Inc Highly potent acid alpha-glucosidase with enhanced carbohydrates
EP3215499B1 (en) 2014-11-05 2021-01-20 Emergent Virology LLC Iminosugars useful for the treatment of viral diseases
KR102510941B1 (en) 2015-12-30 2023-03-20 아미쿠스 세라퓨틱스, 인코포레이티드 Enriched acid alpha-glucosidase for the treatment of Pompe disease
KR102343162B1 (en) 2016-03-30 2021-12-23 아미쿠스 세라퓨틱스, 인코포레이티드 Selection method for high M6P recombinant protein
KR102618519B1 (en) 2016-03-30 2023-12-28 아미쿠스 세라퓨틱스, 인코포레이티드 Formulations comprising recombinant acid alpha-glucosidase

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4611058A (en) * 1980-12-30 1986-09-09 Bayer Aktiengesellschaft Process for the preparation of 1,5-didesoxy-1,5-imino-D-glucitol and N-derivatives thereof
WO1991017145A1 (en) * 1990-05-07 1991-11-14 G.D. Searle & Co. Process for preparation of 1,5-(alkylimino)-1,5-dideoxy-d-glucitol and derivatives thereof
WO1995019172A1 (en) * 1994-01-13 1995-07-20 G.D. Searle & Co. Use of n-alkyl derivatives of 1,5-dideoxy-1,5-imino-d-glucitol for the treatment of hepatitis b virus infections
WO1998035685A1 (en) * 1997-02-14 1998-08-20 G.D. Searle And Co. Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
WO1999029321A1 (en) * 1997-12-11 1999-06-17 The Chancellor, Masters And Scholars Of The University Of Oxford Inhibition of membrane-associated viral replication
WO1999040916A1 (en) * 1998-02-12 1999-08-19 G.D. Searle & Co. Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU33730B (en) 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
GB1555654A (en) 1977-06-25 1979-11-14 Exxon Research Engineering Co Agricultural burner apparatus
US4065562A (en) 1975-12-29 1977-12-27 Nippon Shinyaku Co., Ltd. Method and composition for reducing blood glucose levels
US4012448A (en) 1976-01-15 1977-03-15 Stanford Research Institute Synthesis of adriamycin and 7,9-epiadriamycin
NO154918C (en) 1977-08-27 1987-01-14 Bayer Ag ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE DERIVATIVES OF 3,4,5-TRIHYDROXYPIPERIDINE.
GB2020278B (en) 1978-05-03 1983-02-23 Nippon Shinyaku Co Ltd Moranoline dervitives
JPS5562004A (en) 1978-11-02 1980-05-10 Kureha Chem Ind Co Ltd Control agent against plant viral disease
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
ZA822995B (en) 1981-05-21 1983-12-28 Wyeth John & Brother Ltd Slow release pharmaceutical composition
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
EP0252962B1 (en) 1985-12-23 1995-08-23 Fred Hutchinson Cancer Research Center Regulating retroviral replication, infection, and pathogenesis
GB2186485B (en) 1986-02-13 1988-09-07 Ethical Pharma Ltd Slow release formulation
DE3611841A1 (en) 1986-04-09 1987-10-15 Bayer Ag METHOD FOR PRODUCING 1-DESOXYNOJIRIMYCIN AND ITS N-DERIVATIVES
US5039667A (en) * 1987-08-07 1991-08-13 The Governors Of The University Of Alberta Antiviral therapy for hepatitis B with 2',3'-dideoxypurine nucleosides
US4848430A (en) * 1987-09-28 1989-07-18 Leski Lenet Tire snow belt
DE3814549A1 (en) * 1987-10-30 1989-05-18 Bayer Ag N-SUBSTITUTED DERIVATIVES OF 1-DESOXYNOJIRIMYCIN AND 1-DESOXYMANNONOJIRIMYCIN, METHOD FOR THE PRODUCTION AND USE THEREOF IN MEDICINAL PRODUCTS
DE3737523A1 (en) * 1987-11-05 1989-05-18 Bayer Ag USE OF SUBSTITUTED HYDROXYPIPERIDINES AS ANTIVIRAL AGENTS
US4849430A (en) 1988-03-09 1989-07-18 Monsanto Company Method of inhibiting virus
DK175094B1 (en) 1987-12-21 2004-06-01 Monsanto Co Use of the N-butyl derivative of deoxynojirimycin for the preparation of pharmaceutical composition
FI101344B (en) 1988-03-31 1998-06-15 Tanabe Seiyaku Co The method comprises preparing a preparation from which a pharmaceutically active substance is released in a controlled manner
US5041441A (en) 1988-04-04 1991-08-20 The Regents Of The University Of Michigan Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol
EP0350012A3 (en) 1988-07-08 1990-09-05 Meiji Seika Kaisha Ltd. Antiviral composition
US5144037A (en) 1988-11-03 1992-09-01 G. D. Searle & Co. 1,5-dideoxy-1,5-imino-d-glucitol derivatives
US5003072A (en) 1988-11-03 1991-03-26 G. D. Searle & Co. 1,5-dideoxy-1,5-imino-D-glucitol derivatives
US5221746A (en) 1988-11-03 1993-06-22 G. D. Searle & Co. 1,5-dideoxy-1,5-imino-D-glucitol derivatives
US5310745A (en) 1988-11-03 1994-05-10 G. D. Searle & Co. Antiviral compounds
US4957926A (en) 1988-12-22 1990-09-18 Monsanto Company Method of treating herpesviruses
US5132291A (en) * 1989-01-24 1992-07-21 Gensia Pharmaceuticals, Inc. Antivirals and methods for increasing the antiviral activity of azt
US5011829A (en) 1989-06-02 1991-04-30 G. D. Searle & Co. Pharmaceutical composition and method of inhibiting virus
WO1991003242A1 (en) * 1989-09-07 1991-03-21 Nippon Shinyaku Co., Ltd. Antiviral drug
US5030638A (en) 1990-02-26 1991-07-09 G. D. Searle & Co. Method of antiviral enhancement
DE4009561A1 (en) 1990-03-24 1991-09-26 Bayer Ag New anti-retroviral desoxy:nojirimycin derivs.
US5536732A (en) 1990-04-27 1996-07-16 Merrell Pharmaceuticals Inc. N-derivatives of 1-deoxy nojirimycin
CA2051855C (en) 1990-09-20 2002-11-26 Roy W. Grabner Process for producing n-substituted-1-deoxynojirimycin
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5190765A (en) 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
DE4307883A1 (en) 1992-03-12 1993-09-23 Westarp Martin Egon Dr Med Use of anti-retroviral substances - to treat motor-neuronal diseases
ZA931934B (en) 1992-03-18 1993-03-18 Us Bioscience Compostitions of N-(phosphonoacetyl)-L-aspartic acid and methods of their use as broad spectrum antivirals
IL105090A (en) 1992-03-18 1998-08-16 Us Bioscience N-(phosphonoacetyl)-l-aspartic acid as broad spectrum antiviral
US5331096A (en) 1992-04-01 1994-07-19 G. D. Searle & Co. 2- and 3-sulfur derivatives of 1,5-iminosugars
US5258518A (en) 1992-04-01 1993-11-02 G. D. Searle & Co. 2-substituted tertiary carbinol derivatives of deoxynojirimycin
US5261724A (en) * 1992-04-03 1993-11-16 Grammer Ag Sprung seat
WO1994004546A1 (en) 1992-08-14 1994-03-03 Nippon Shinyaku Co., Ltd. Moranoline derivative
US5265356A (en) * 1992-10-14 1993-11-30 Winter Kent L Snowplow and hydraulic system for same
FR2700267B1 (en) 1993-01-13 1995-03-17 Oreal N-acyl amino deoxy alditols, and their use in cosmetic or dermopharmaceutical compositions.
WO1994021595A1 (en) 1993-03-17 1994-09-29 Kao Corporation Amine derivative and dermatologic preparation containing the same
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
US5750648A (en) * 1993-08-20 1998-05-12 G.D. Searle & Co. Retroviral protease inhibitors and combinations thereof
AU7518694A (en) 1993-08-20 1995-03-21 G.D. Searle & Co. Retroviral protease inhibitors and combinations thereof
US6093702A (en) 1993-12-20 2000-07-25 The United States Of America As Represented By The Department Of Health And Human Services Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread
AU1876095A (en) 1994-02-25 1995-09-11 G.D. Searle & Co. Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus
US5451679A (en) 1994-03-08 1995-09-19 G. D. Searle & Co. 2-chloro and 2-bromo derivatives of 1,5-iminosugars
US5491261A (en) * 1994-07-01 1996-02-13 Ciba-Geigy Corporation Poly-perfluoroalkyl-substituted alcohols and acids, and derivatives thereof
US5622342A (en) * 1994-10-26 1997-04-22 Mills; James E. Versatile apparatus for supporting cameras, spotting scopes and other devices
US5703058A (en) 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
FR2731150B1 (en) 1995-03-03 1997-04-18 Oreal USE OF AMPHIPHILIC COMPOUNDS AS A THICKENING AGENT FOR NON-AQUEOUS MEDIA
US5763470A (en) 1995-06-07 1998-06-09 Sugen Inc. Benzopyran compounds and methods for their use
PT831852E (en) * 1995-06-07 2007-02-28 Uab Research Foundation Nucleosides with anti-hepatitis b virus activity
WO1997000881A1 (en) 1995-06-22 1997-01-09 Nippon Shinyaku Co., Ltd. Moranoline derivatives
US5905068A (en) * 1996-09-24 1999-05-18 Abbott Laboratories Retroviral protease inhibiting compounds
US20030100532A1 (en) * 1997-02-14 2003-05-29 Gary S. Jacob Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
US6689759B1 (en) * 1998-02-12 2004-02-10 G. D. Searle & Co. Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy
US20040132161A1 (en) * 1998-04-20 2004-07-08 Finkel Terri H. Methods and compositions for increasing CD4lymphocyte immune responsiveness
CA2362785A1 (en) * 1999-02-12 2001-02-08 G.D. Searle & Co. Glucamine compounds for treating hepatitis virus infections
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4611058A (en) * 1980-12-30 1986-09-09 Bayer Aktiengesellschaft Process for the preparation of 1,5-didesoxy-1,5-imino-D-glucitol and N-derivatives thereof
WO1991017145A1 (en) * 1990-05-07 1991-11-14 G.D. Searle & Co. Process for preparation of 1,5-(alkylimino)-1,5-dideoxy-d-glucitol and derivatives thereof
WO1995019172A1 (en) * 1994-01-13 1995-07-20 G.D. Searle & Co. Use of n-alkyl derivatives of 1,5-dideoxy-1,5-imino-d-glucitol for the treatment of hepatitis b virus infections
WO1998035685A1 (en) * 1997-02-14 1998-08-20 G.D. Searle And Co. Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
WO1999029321A1 (en) * 1997-12-11 1999-06-17 The Chancellor, Masters And Scholars Of The University Of Oxford Inhibition of membrane-associated viral replication
WO1999040916A1 (en) * 1998-02-12 1999-08-19 G.D. Searle & Co. Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BLOCK T M ET AL: "SECRETION OF HUMAN HEPATITIS B VIRUS IS INHIBITED BY THE IMINO SUGAR N-BUTYLDEOXYNOJIRIMYCIN", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,NATIONAL ACADEMY OF SCIENCE. WASHINGTON,US, vol. 91, no. 6, March 1994 (1994-03-01), pages 2235 - 2239, XP000952542, ISSN: 0027-8424 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; May 1998 (1998-05-01), BLOCK TIMOTHY M ET AL: "Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking.", XP002152104, Database accession no. PREV199800265466 *
NATURE MEDICINE, vol. 4, no. 5, May 1998 (1998-05-01), pages 610 - 614, ISSN: 1078-8956 *
PLATT F M ET AL: "N-BUTYLDEOXYNOJIRIMYCIN IS A NOVEL INHIBITOR OF GLYCOLIPID BIOSYNTHESIS. SECRETION OF HUMAN HEPATITIS B VIRUS IS INHIBITED BY THE IMINO SUGAR N-BUTYLDEOXYNOJIRIMYCIN", CHEMTRACTS ORGANIC CHEMISTRY,US,DATA TRACE CHEMISTRY PUBLISHERS, 1994, pages 106 - 107, XP002067581, ISSN: 0895-4445 *
ZITZMANN N ET AL: "IMINO SUGARS INHIBIT THE FORMATION AND SECRETION OF BOVINE VIRAL DIARRHEA VIRUS, A PESTIVIRUS MODEL OF HEPATITIS C VIRUS: IMPLICATIONS FOR THE DEVELOPMENT OF BROAD SPECTRUM ANTI-HEPATITIS VIRUS AGENTS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,NATIONAL ACADEMY OF SCIENCE. WASHINGTON,US, vol. 96, no. 21, 1999, pages 11878 - 11882, XP000952534, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
US20030220299A1 (en) 2003-11-27
US20060264468A1 (en) 2006-11-23
EP1165080A2 (en) 2002-01-02
DE60039729D1 (en) 2008-09-11
ES2311921T3 (en) 2009-02-16
ATE402701T1 (en) 2008-08-15
CA2362914C (en) 2009-04-14
CA2362914A1 (en) 2000-08-17
US6545021B1 (en) 2003-04-08
HK1043311A1 (en) 2002-09-13
JP2002536407A (en) 2002-10-29
AU3595500A (en) 2000-08-29
WO2000047198A2 (en) 2000-08-17

Similar Documents

Publication Publication Date Title
WO2000047198A3 (en) Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
CA2433878A1 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
AP1782A (en) Use of compounds ?-D or ?-L nucleoside for treating hepatitis C virus.
WO2004007512A3 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2004000858A3 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2004003138A3 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
BR9907882A (en) Use of unsubstituted 1,5-dideoxy-1,5-imino-d-glucitol compounds for the treatment of hepatitis virus infections
WO2004009020A3 (en) Pyrrolopyrimidine thionucleoside analogs as antivirals
BR0307712A (en) Compound, composition and use in the treatment of flaviviridae infections and abnormal cell proliferation
EP1128832A4 (en) Compounds, compositions and methods for treating or preventing viral infections and associated diseases
WO2004002422A3 (en) 2’-c-methyl-3’-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
MXPA03008623A (en) Pharmaceutical combinations for the treatment of cancer.
WO2002092006A3 (en) Nucleic acid-based compounds and methods of use thereof
WO2001008672A3 (en) Glucamine compounds for treating hepatitis virus infections
AU6169298A (en) Use of (n)-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combinationtherapy for treating hepatitis virus infections
AU2003237088A8 (en) Compounds, compositions and methods for treating or preventing viral infections and associated diseases
WO2003020222A3 (en) PYRROLO[2,3-d]PYRIMIDINES FOR INHIBITING RNA-DEPENDENT RNA VIRAL POLYMERASE
WO2004064784A3 (en) Composition and method for preventing or treating a virus infection
ZA991142B (en) Use of N-substituted-1,5-dideoxy-1,5-imino-D-Glucitol compounds for treating hepatitis virus infections.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000914585

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2362914

Country of ref document: CA

Ref country code: CA

Ref document number: 2362914

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: JP

Ref document number: 2000 598151

Kind code of ref document: A

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000914585

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000914585

Country of ref document: EP